COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,159 Articles (22,703 medRxiv, 8,456 bioRxiv)

Most recent first Previous |  Page 1130: Articles 11291-11300  | Next

Cumulative incidence of SARS-CoV-2 and associated risk factors among healthcare workers in the Eastern Cape, South Africa
Stead, D. F., Adeniyi, O. V., Singata-Madliki, M., Abrahams, S., Batting, J., Jelliman, E., Parrish, A. G.
10.1101/2021.11.08.21265966 — Posted: 2021-11-09
Ad26.COV2.S breakthrough infections induce high titers of antibodies capable of neutralizing variants of concern
Kitchin, D., Richardson, S. I., van der Mescht, M. A., Motlou, T., Mzindle, N., Moyo-Gwete, T., Makhado, Z., Ayres, F., Manamela, N. P., Spencer, H., Lambson, B., Oosthuysen, B., Mennen, M., Skelem, S., Williams, N., Ntusi, N. A. B., Burgers, W. A., Gray, G. G., Bekker, L.-G., Boswell, M. T., Rossouw, T. M., Ueckermann, V., Moore, P. L.
10.1101/2021.11.08.21266049 — Posted: 2021-11-09
Understanding COVID-19 trajectories from a nationwide linked electronic health record cohort of 56 million people: phenotypes, severity, waves & vaccination
Thygesen, J. H., Tomlinson, C. R., Hollings, S., Mizani, M. A., Handy, A., Akbari, A., Banerjee, A., Cooper, J. A., Lai, A. G., Li, K., Mateen, B. A., Sattar, N., Sofat, R., Torralbo, A., Wu, H., Wood, A., Sterne, J. A., Pagel, C., Whiteley, W., Sudlow, C., Hemingway, H., Denaxas, S., CVD-COVID-UK Consortium
10.1101/2021.11.08.21265312 — Posted: 2021-11-09
Vaccine effectiveness of Pfizer-BioNTech and Oxford-AstraZeneca to prevent severe COVID-19 in Costa Rica by September and October 2021: A nationwide, observational study of hospitalisations prevalence.
Rosero-Bixby, L.
10.1101/2021.11.08.21266087 — Posted: 2021-11-09
Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: a space-time study
Padellini, T., Jersakova, R., Diggle, P. J., Holmes, C., King, R., Lehmann, B., Mallon, A.-M., Nicholson, G., Richardson, S., Blangiardo, M.
10.1101/2021.11.09.21266054 — Posted: 2021-11-09
Immunity to COVID-19 in India through vaccination and natural infection
Sarraf, T. R., Maity, S., Ghosh, A., Bhattacharjee, S., Pani, A., Saha, K., Chattopadhyay, D., Ghosh, G., Sen, M.
10.1101/2021.11.08.21266055 — Posted: 2021-11-09
The effects of the first national lockdown in England on geographical inequalities in the evolution of COVID-19 case rates: An ecological study
Welsh, C. E., Albani, V., Matthews, F. E., Bambra, C.
10.1101/2021.11.09.21266122 — Posted: 2021-11-09
SARS-CoV-2 triggered excessive inflammation and abnormal energy metabolism in gut microbiota
Zhou, T.
10.1101/2021.11.08.467715 — Posted: 2021-11-09
The preparedness and response to COVID-19 in a quaternary Intensive Care Unit in Australia: perspectives and insights from frontline critical care clinicians
SUNDARARAJAN, K., Bi, P., Milazzo, A., Poole, A., Reddi, B., Mahmood, A.
10.1101/2021.11.05.21265998 — Posted: 2021-11-09
The effect of notification window length on the epidemiological impact of COVID-19 contact tracing mobile applications
Leng, T., Hill, E. M., Keeling, M. J., Tildesley, M. J., Thompson, R. N.
10.1101/2021.11.08.21266079 — Posted: 2021-11-09

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).